Shield Therapeutics will get $7.9 million when its Chinese partner applies to sell a drug.
Shield Therapeutics 將從其中國合作夥伴北京奧賽康藥業有限公司（ASK）獲得一筆重大的提振，即一筆790萬美元的里程碑付款。
Shield Therapeutics is set to receive a significant boost, a $7.9 million milestone payment, from its Chinese partner, Beijing Aosaikang Pharmaceutical Co.
這筆款項的觸發是因為ASK計劃在中國提交ACCURFeR（一種缺鐵症藥物）的上市許可申請。
Ltd (ASK).
預計將於2026年第一季向中國國家藥品監督管理局（NMPA）提交該申請。
This payment is triggered by ASK's plan to submit a marketing authorization application for ACCRUFeR, an iron deficiency drug, in China.
重要的是，此申請將包括來自Shield第三期臨床試驗的兒科數據，該數據曾幫助ACCURFeR獲得美國FDA批准用於10歲及以上兒童。
The filing with the China National Medical Products Administration (NMPA) is anticipated in the first quarter of 2026.
這筆790萬美元的款項預計將於2026年1月31日前到帳。
Importantly, this application will include pediatric data from Shield's Phase 3 clinical trials, which previously helped secure US FDA approval for children aged 10 and older.
Shield Therapeutics計劃利用這些資金結算並終止其AOP里程碑貨幣化協議。
The $7.9 million is expected by January 31, 2026.
這一戰略舉措旨在簡化Shield的資本結構並改善其財務狀況。
Shield Therapeutics intends to use these funds to settle and terminate its AOP Milestone Monetisation Agreement.
2020年的原始授權協議涵蓋了ACCURFeR在中國、香港、澳門和台灣的開發和商業化。
This strategic move aims to simplify Shield's capital structure and improve its financial health.
修訂後的協議還規定了潛在的額外里程碑和高達10%的淨銷售額版稅，取代了早期一筆較大的里程碑。
The original 2020 licensing deal covered ACCRUFeR's development and commercialization across China, Hong Kong, Macau, and Taiwan.
ACCURFeR仍然是一種創新的治療方法，專利保護期將持續到2030年代中期。
The revised agreement also outlines potential additional milestones and royalties up to 10% on net sales, replacing an earlier, larger milestone.
